Next 10 |
2024-06-26 11:19:28 ET Summary Arcellx is advancing Anito-cel in a pivotal Phase 2 trial for relapsed or refractory multiple myeloma, showing promising early results. Anito-cel has demonstrated a 100% overall response rate and a 76% complete response rate in early trials. The ...
2024-06-25 14:07:48 ET More on iShares Russell 2000 ETF: IWM: Small Caps Look Unattractive With Deteriorating Earnings Outlook IWM: Favor Small Caps Over The Technology Sector IWM: Not The Economy For Underdogs (Rating Downgrade) Gap between growth and small-...
2024-06-06 10:47:18 ET More on 2seventy bio 2seventy bio, Inc. (TSVT) Q1 2024 Earnings Call Transcript 2seventy Bio: Maximizing ABECMA's Potential To Fuel A Turnaround Bristol-Myers posts Q1 beat despite growth headwinds Bristol Myers, 2seventy bio's Abecma a...
2024-05-31 06:00:08 ET Biren Amin from Piper Sandler issued a price target of $70.00 for ACLX on 2024-05-31 05:01:00. The adjusted price target was set to $70.00. At the time of the announcement, ACLX was trading at $52.24. The overall price target consensus is at $59.50...
2024-05-27 12:32:15 ET InvestorPlace - Stock Market News, Stock Advice & Trading Tips For those seeking to decipher best speculative opportunities in the market, biotech stocks with breakthrough potential may offer plenty of firepower. Let’s get some of the bad st...
2024-05-25 10:24:03 ET More on AbbVie, Amgen, etc. Bristol Myers Squibb: 5.5% Yielder Has Been Crushed In What Could Be A Generational Buying Opportunity Why Gilead Sciences' 4.6% Yield Doesn't Make The Cut For Smart Investors Amgen Stock: Poised To Break Out (Techni...
2024-05-15 08:00:04 ET Benjamin Burnett from Stifel Nicolaus issued a price target of $83.00 for ACLX on 2024-05-15 06:37:00. The adjusted price target was set to $83.00. At the time of the announcement, ACLX was trading at $50.62. The overall price target consensus is a...
2024-05-14 11:24:32 ET More on BioNTech, Moderna, etc. BioNTech SE 2024 Q1 - Results - Earnings Call Presentation BioNTech SE (BNTX) Q1 2024 Earnings Call Transcript Regeneron: Dissecting The First Quarter Results And Regulatory Setbacks Moderna announces del...
2024-05-10 07:10:29 ET More on Arcellx Gilead's Kite, Arcellx share phase 3 trial design for CAR-T multiple myeloma asset Seeking Alpha’s Quant Rating on Arcellx Historical earnings data for Arcellx Financial information for Arcellx Read the ...
2024-05-09 17:13:21 ET More on Gilead Sciences, Arcellx Gilead Sciences, Inc. (GILD) Q1 2024 Earnings Call Transcript Gilead Sciences, Inc. 2024 Q1 - Results - Earnings Call Presentation Gilead Q1 Earnings Preview: Most Gains Wiped Out - Cause For Concern? Gi...
News, Short Squeeze, Breakout and More Instantly...
2024-05-31 06:00:08 ET Biren Amin from Piper Sandler issued a price target of $70.00 for ACLX on 2024-05-31 05:01:00. The adjusted price target was set to $70.00. At the time of the announcement, ACLX was trading at $52.24. The overall price target consensus is at $59.50...
2024-05-15 08:00:04 ET Benjamin Burnett from Stifel Nicolaus issued a price target of $83.00 for ACLX on 2024-05-15 06:37:00. The adjusted price target was set to $83.00. At the time of the announcement, ACLX was trading at $50.62. The overall price target consensus is a...